Chlamydia Infection Diagnostics Market - Top Companies and Manufacturers

  • Report ID: 6570
  • Published Date: Oct 18, 2024
  • Report Format: PDF, PPT

Companies Dominating the Chlamydia Infection Diagnostics Landscape

    Key players in the chlamydia infection diagnostics market employ several tactics such as new product launches, technological advancements, partnerships and collaborations, regional expansion, and more to earn high profits. Industry giants are investing heavily in research and development activities to introduce innovative diagnostic solutions. Strategic collaborations with other players and research organizations are also aiding them to expand their product folios. Furthermore, regional expansion strategies are helping them to tap into emerging markets to cater to a larger audience base.

    Some of the key players include:

    • Visby Medical
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech Plc.
    • Qiagen Inc.
    • ELITechGroup
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Hologic, Inc.
    • QuidelOrtho Corporation.
    • Siemens Healthineers
    • DiaSorin S.p.A.
    • F. Hoffmann-La Roche Ltd

Browse Key Market Insights with Data Illustration:

In the News

  • In May 2022, Abbot Laboratories received an FDA clearance for its Alinity m STI Assay solution. It is a first-of-its-kind multiplex test that aids in addressing rising STI rates.
  • In August 2021, Visby Medical received a 510(k) clearance and waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) from the US Food and Drug Administration to commercialize its quick, single-use polymerase chain reaction (PCR) diagnostic test. This product is vital for multiplexed detection of sexually transmitted infections including chlamydia trachomatis, using a self-collected vaginal swab.

Author Credits:  Radhika Pawar


  • Report ID: 6570
  • Published Date: Oct 18, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The global chlamydia infection diagnostics market will be valued at USD 1.7 billion in 2025.

Expanding at a CAGR of 7.5%, the global market is expected to increase from USD 1.6 billion in 2024 to USD 4.1 billion by 2037.

Some leading companies are Visby Medical, Abbott Laboratories, Thermo Fisher Scientific Inc., Trinity Biotech Plc., Qiagen Inc., and Becton, Dickinson and Company.

The genital chlamydia infection segment is estimated to capture a strong 72.5% of the market share through 2037.

North America is expected to hold 39.0% of the global market share through 2037.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample